Please assess the completion status of the following clinical trial:

Trial Title: Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed small cell lung cancer (SCLC)~  * Recurrent extensive stage disease~ * No mixed histology~* Measurable disease~  * At least 1 bidimensionally measurable, non-central nervous system (CNS), indicator lesion confirmed by CT scan or MRI~* Sensitive disease~  * Responded to prior first-line therapy AND relapsed ≥ 60 days after response (90 days after initiation of first-line therapy)~* Eligible for high-dose chemotherapy~* No symptomatic brain metastases affecting performance status~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Eastern Cooperative Oncology Group (ECOG) 0-2~Life expectancy~* At least 2 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Hematocrit \> 35% (without transfusion)~Hepatic~* Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times normal\*~* Alkaline phosphatase ≤ 2 times normal\*~* Bilirubin ≤ 2.0 mg/dL~* Albumin \> 2.5 g/dL~* Hepatitis B surface antigen negative~* No significant hepatic disease Note: \*≤ 5 times upper limit of normal if liver metastases are present~Renal~* Creatinine clearance ≥ 40 mL/min~Cardiovascular~* No history of cardiac arrhythmias~* No congestive heart failure~* No ischemic heart disease~* No stroke or other embolic disease requiring daily treatment that would preclude study participation~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after study participation~* HIV negative~* No known seizure disorder~* No active infection requiring systemic therapy within the past 2 weeks~* No known hypersensitivity to topotecan hydrochloride~* No medical or psychiatric condition that would preclude study participation~* No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage A low-grade prostate cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* More than 4 weeks since prior antineoplastic and/or myelosuppressive chemotherapy~* No more than 1 prior chemotherapy regimen (except for adjuvant chemotherapy) for SCLC~* No prior topotecan hydrochloride~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* More than 2 months since prior investigational agent~* No other concurrent investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).